Biosimulation Market by Product ,Application & by End Users – Global Forecast to 2020

The global biosimulation market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 million in 2015, at a CAGR of 15.29% between 2015 and 2020. By product, the market includes software and services. Based on application, the market is segmented into drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production). The drug development application segment is further classified into preclinical testing and clinical trials. Preclinical testing includes ADME/Tox and PK/PD applications. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment is expected to grow at the highest rate.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in the global biosimulation market in 2015. Europe is expected to register the fastest growth.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/biosimulation-market-by-product-software-molecular-modeling-pb2Fpk-pkpd-trial-design-toxicity-prediction-in-house-contract-service-application-drug-discovery-26-development-preclinical-clinical-trial-26-by-end-users—global-forecast-to-2020

Market growth is majorly driven by the availability of R&D investments in biotechnology and pharmaceutical industries. Other growth factors include the need to curtail drug discovery & development costs, technological advancements, growth in the biologics and biosimilars markets, and the increased use of personalized medicines.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global biosimulation market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates. The report provides qualitative insights about growth rates, and market drivers for all subsegments. It maps market sizes and growth rates for each subsegment and identifies segments poised for rapid growth in each geographic segment. The report also includes company profiles of market leaders.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:

 

  • Product Development: Product portfolios of the top players in the biosimulation market.
  • Competitive Assessment: In-depth assessment of the business segments and product portfolios of the leading players in the biosimulation market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biosimulation products and services across geographies.

 

Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/biosimulation-market-by-product-software-molecular-modeling-pb2Fpk-pkpd-trial-design-toxicity-prediction-in-house-contract-service-application-drug-discovery-26-development-preclinical-clinical-trial-26-by-end-users—global-forecast-to-2020
Table of content

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.2.1 MARKETS COVERED 16
1.2.2 YEARS CONSIDERED FOR THE STUDY 16
1.3 CURRENCY 17
1.4 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 MARKET SIZE ESTIMATION 19
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.3 MARKET SHARE ESTIMATION 23
2.3.1 KEY DATA FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.3 ASSUMPTIONS FOR THE STUDY 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHTS 29
4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOSIMULATION MARKET 29
4.2 LIFE CYCLE ANALYSIS, BY REGION (2015–2020) 30
5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.2 MARKET SEGMENTATION 33
5.2.1 BY PRODUCT 33
5.2.2 BY APPLICATION 34
5.2.3 BY END USER 34
5.3 MARKET DYNAMICS 35
5.3.1 DRIVERS 36
5.3.1.1 Growth in the pharmaceutical and biotechnology industries 36
5.3.1.2 Increase in R&D investments in the pharmaceutical and biotechnology industries 36
5.3.1.3 Technological advancements 37
5.3.1.4 Need to curtail drug discovery and development costs 37
5.3.1.5 Growth in the biologics and biosimilars market and increased use of personalized medicines 37
5.3.2 RESTRAINTS 39
5.3.2.1 Lack of standardization 39
5.3.2.2 Lack of trained professionals 39
5.3.3 OPPORTUNITIES 40
5.3.3.1 Emerging applications 40
5.3.4 CHALLENGES 41
5.3.4.1 Limited knowledge of biological systems and processes 41
5.3.5 TRENDS 42
5.3.5.1 Collaborations of universities and research labs with suppliers 42

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/biosimulation-market-by-product-software-molecular-modeling-pb2Fpk-pkpd-trial-design-toxicity-prediction-in-house-contract-service-application-drug-discovery-26-development-preclinical-clinical-trial-26-by-end-users—global-forecast-to-2020
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports